AI MARKET SCANNING

Minerva Neurosciences Inc

📅 Next Catalyst: Nov 11, 2026 (🌙 Close) 🏛️ NASDAQ 📁 Health Technology 🏭 Pharmaceuticals Major
AVG HISTORICAL GAP -0.18%
MAX GAP RECORD +6.08%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $NERV
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 11, 2026 Earnings Release 2026-11-11 (UNDETERMINED) 🔮 UPCOMING 🔒
Aug 07, 2026 Earnings Release 2026-08-07 (BEFORE OPEN)
-1.13%
May 05, 2026 Earnings Release 2026-05-05 (BEFORE OPEN)
+0.95%
Mar 11, 2026 Earnings Release 2026-03-11 (BEFORE OPEN)
-3.65%
Nov 05, 2025 Earnings Release 2025-11-05 (BEFORE OPEN)
-4.63%
Aug 14, 2025 Earnings Release 2025-08-14 (AFTER CLOSE)
+4.74%
May 13, 2025 Earnings Release 2025-05-13 (BEFORE OPEN)
+1.78%
Feb 25, 2025 Earnings Release 2025-02-25 (BEFORE OPEN)
+0.56%

VOLATILITY & GAP BIAS

AVG GAP MOVE 2.8%
Bullish Gaps (4)
Bearish Gaps (6)
Neutral / Flat (4)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $NERV

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗